NOVAVAX INC Severance Costs
NOVAVAX INC (NVAX) reported Severance Costs of $1.12 million for the 3-month period ending 2024-06-30, per its 10-Q filed 2024-08-08.
Discontinued › Expense Statement › Operating Expenses
us-gaap:SeveranceCosts1 · last filed 2024-08-08
- NOVAVAX INC severance costs for the quarter ending 2024-06-30 was $1.12M, a 75.90% decline year-over-year.
- NOVAVAX INC severance costs for the quarter ending 2024-03-31 was $4.40M.
- NOVAVAX INC severance costs for the quarter ending 2023-12-31 was $0.00.
- NOVAVAX INC severance costs for the quarter ending 2023-09-30 was -$140.00K.
- NOVAVAX INC severance costs for fiscal 2023 was $4.50M.
| Period end | Severance Costs 3 month | Severance Costs 3 month as first filed | Severance Costs 6 month | Severance Costs 9 month | Severance Costs 12 month |
|---|---|---|---|---|---|
| 2024-06-30 | $1.12M 10-Q · filed 2024-08-08 | $5.52M 10-Q · filed 2024-08-08 | $5.52M derived: sum of 3 quarters · filed 2024-08-08 | $5.38M derived: sum of 4 quarters · filed 2024-08-08 | |
| 2024-03-31 | $4.40M 10-Q · filed 2024-05-10 | $4.40M derived: sum of 2 quarters · filed 2024-05-10 | $4.26M derived: sum of 3 quarters · filed 2024-05-10 | $8.90M derived: sum of 4 quarters · filed 2024-08-08 | |
| 2023-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-28 | -$140.00K derived: sum of 2 quarters · filed 2024-02-28 | $4.50M derived: sum of 3 quarters · filed 2024-08-08 | $4.50M 10-K · filed 2024-02-28 | |
| 2023-09-30 | -$140.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-09 | $4.50M derived: sum of 2 quarters · filed 2024-08-08 | $4.50M 10-Q · filed 2023-11-09 | ||
| 2023-06-30 | $4.64M 10-Q · filed 2024-08-08 | $3.60M 10-Q · filed 2023-08-08 | $4.64M 10-Q · filed 2024-08-08 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Vir Biotechnology, Inc. (VIR) | United States | $1.814B | -6.85 |
| Hemab Therapeutics Holdings, Inc. (COAG) | United States | $1.672B | |
| Immunocore Holdings plc (IMCR) | $1.613B | -90.43 | |
| Taysha Gene Therapies, Inc. (TSHA) | United States | $1.564B | -14.80 |
| Vericel Corp (VCEL) | United States | $2.011B | 93.97 |
| Inhibrx Biosciences, Inc. (INBX) | United States | $1.477B | -10.08 |
| Maze Therapeutics, Inc. (MAZE) | United States | $1.457B | -12.40 |
| RECURSION PHARMACEUTICALS, INC. (RXRX) | United States | $2.080B | -3.78 |
| Kodiak Sciences Inc. (KOD) | United States | $2.090B | -10.12 |
| ADMA BIOLOGICS, INC. (ADMA) | United States | $2.131B | 11.16 |